This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Titan Medical マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Paul Cataford

最高経営責任者

US$165.0k

報酬総額

CEO給与比率	72.1%
CEO在任期間	1.3yrs
CEOの所有権	0.1%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

Revenues Working Against Titan Medical Inc.'s (TSE:TMD) Share Price

Jan 09

There's No Escaping Titan Medical Inc.'s (TSE:TMD) Muted Revenues

Sep 25

CEO報酬分析

Titan Medical の収益と比較して、Paul Cataford の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	US$9m
Dec 31 2023	US$165k	US$119k	US$7m
Sep 30 2023	n/a	n/a	-US$1m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	US$791k	US$175k	-US$43m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$457k	US$25k	-US$15m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$20k	n/a	-US$24m

報酬と市場: Paulの総報酬 ($USD 165.04K ) は、 Canadian市場 ($USD 171.96K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Paul Cataford (60 yo)

1.3yrs

在職期間

US$165,041

報酬

Mr. Paul G. Cataford, ICD D, MBA, B.Sc. (Engineering) is Interim President & CEO of Titan Medical Inc. since June 01, 2023 and was its Chairman from June 01, 2023 to October 2, 2024 and served as its Direc...

取締役

名称	ポジション	在職期間	報酬	所有権
Anthony Giovinazzo	Lead Independent Director	4.1yrs	US$70.02k	0.011% CA$ 599.8
Cathy Steiner	Independent Director	3.3yrs	US$70.46k	データなし
Cary Vance	Director	less than a year	US$574.47k	0% CA$ 0
Kevin Stepp	Member of Surgeon Advisory Board	no data	データなし	データなし
Ricardo Estape	Member of Surgeon Advisory Board	2.9yrs	データなし	データなし
J. Magnuson	Member of Surgeon Advisory Board	2.9yrs	データなし	データなし
Arleen Song	Member of Surgeon Advisory Board	2.9yrs	データなし	データなし
Daniel O'Brien	Independent Director	1.2yrs	US$22.98k	0.27% CA$ 15.6k

2.9yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: TMDの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

This company is no longer active

Titan Medical マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Conavi Medical Corp. Appoints Thomas Looby as Chief Executive Officer

Titan Medical Inc. Announces Resignations of Directors

Titan Medical Inc., Annual General Meeting, Sep 30, 2024

Titan Medical Inc., Annual General Meeting, Sep 30, 2024

High number of new and inexperienced directors

Titan Medical Inc. Appoints Daniel O’Brien as A New Independent Member to Its Board of Directors

Recent updates

Conavi Medical Corp. Appoints Thomas Looby as Chief Executive Officer

Titan Medical's Common Shares Expected to be Delisted from the Toronto Stock Exchange, Effective as of Close of Markets on or around October 16, 2024 upon Receipt of Final Approval of the TSX and the TSX-V

Titan Medical Inc. Announces Resignations of Directors

Titan Medical BoD Approves Voluntary Delisting of Common Shares from TSX

Titan Medical Inc., Annual General Meeting, Sep 30, 2024

Titan Medical Inc., Annual General Meeting, Sep 30, 2024

Conavi Medical Inc. entered into a definitive amalgamation agreement to acquire Titan Medical Inc. (TSX:TMD) in a reverse merger transaction.

Titan Medical Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Revenues Working Against Titan Medical Inc.'s (TSE:TMD) Share Price

New minor risk - Share price stability

New major risk - Market cap size

There's No Escaping Titan Medical Inc.'s (TSE:TMD) Muted Revenues

High number of new and inexperienced directors

Titan Medical Inc. Appoints Daniel O’Brien as A New Independent Member to Its Board of Directors

Titan Medical Inc. Announces Executive Terminations

Titan Medical Announces Receipt of Nasdaq Listing Determination

Third quarter 2022 earnings released: US$0.093 loss per share (vs US$0.077 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.09 loss per share (vs US$0.077 loss in 3Q 2021)

Titan Medical Inc. to Report Q3, 2022 Results on Nov 10, 2022

Titan Medical Inc. Announces Publication of Patent Application Expanding Commitment to Continued Innovation in Single Access Robotic Assisted Surgery

First half 2022 earnings released

High number of new and inexperienced directors

Titan Medical Inc. to Report Q2, 2022 Results on Aug 11, 2022

Titan Medical Inc. Announces Management Changes, Effective July 1, 2022

Titan Medical Gets 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Titan Medical Provides Update to Enos Project Timeline

Titan Medical Announces Departure of Perry Genova, Senior Vice President of Research and Product Development

Titan Medical Inc., Annual General Meeting, Jun 08, 2022

Titan Medical Expands Patent Portfolio to More Than 200 Patents and Applications and Clarifies Third-Party Licensing Strategy

Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Titan Medical Inc. has completed a Composite Units Offering in the amount of $20.004 million.

Titan Medical Inc. to Report Q4, 2020 Results on Feb 22, 2021

Titan Medical Inc. Provides Regulatory Update

Titan Medical Provides Update on Medtronic Development and License Agreement

Titan Medical Inc. Announces Board Appointments

Titan Medical Inc. Approves Election of Directors

Titan Medical Inc Announces the Launch of A New Name and Brand Identity for Its Robotic Surgical System Under Development

Titan Medical Confirms Receipt of Deficiency Notice from Nasdaq

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24